超声指导下针灸电刺激联合白虎汤化裁方早期干预(DAIRIES方案)对脑梗死急性期火热证患者神经功能缺损的影响

注册号:

Registration number:

ITMCTR2200005820

最近更新日期:

Date of Last Refreshed on:

2022-04-07

注册时间:

Date of Registration:

2022-04-07

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

超声指导下针灸电刺激联合白虎汤化裁方早期干预(DAIRIES方案)对脑梗死急性期火热证患者神经功能缺损的影响

Public title:

Effect of Acupuncture and Electrical Stimulation under the Guidance of Ultrasound Combined with Baihu Decoction (DAIRIES Program) on Neurological impairment in Patients with Fiery-heat Syndrome in the Acute Stage of Cerebral Infarction

注册题目简写:

English Acronym:

研究课题的正式科学名称:

超声指导下针灸电刺激联合白虎汤化裁方早期干预(DAIRIES方案)对脑梗死急性期火热证患者神经功能缺损的影响

Scientific title:

Effect of Acupuncture and Electrical Stimulation under the Guidance of Ultrasound Combined with Baihu Decoction (DAIRIES Program) on Neurological impairment in Patients with Fiery-heat Syndrome in the Acute Stage of Cerebral Infarction

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

ChiCTR2200058340 ; ChiMCTR2200005820

申请注册联系人:

刘绛云

研究负责人:

刘绛云

Applicant:

Jiangyun Liu

Study leader:

Jiangyun Liu

申请注册联系人电话:

Applicant telephone:

+8618912979527

研究负责人电话:

Study leader's telephone:

+8618912979527

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

liujiangyun1984@163.com

研究负责人电子邮件:

Study leader's E-mail:

liujiangyun1984@163.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

南京市红山路十字街100号

研究负责人通讯地址:

南京市红山路十字街100号

Applicant address:

100 Cross Street, Hongshan Road, Nanjing

Study leader's address:

100 Cross Street, Hongshan Road, Nanjing

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

Jiangsu Province Academy of Traditional Chinese Medicine

Applicant's institution:

Jiangsu Province Academy of Traditional Chinese Medicine

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

2022-LWKY-004

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件

批准本研究的伦理委员会名称:

江苏省中西医结合医院伦理委员会

Name of the ethic committee:

Ethics Committee of Jiangsu Provincial Hospital on Traditional of Chinese and Western Medicine

伦理委员会批准日期:

Date of approved by ethic committee:

2022/1/28 0:00:00

伦理委员会联系人:

曹晓娟

Contact Name of the ethic committee:

Xiaojuan Cao

伦理委员会联系地址:

南京市红山路十字街100号

Contact Address of the ethic committee:

100 Cross Street, Hongshan Road, Nanjing

伦理委员会联系人电话:

Contact phone of the ethic committee:

18136871168

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

江苏省中西医结合医院

Primary sponsor:

Jiangsu Provincial Hospital on Traditional of Chinese and Western Medicine

研究实施负责(组长)单位地址:

南京市红山路十字街100号

Primary sponsor's address:

100 Cross Street, Hongshan Road, Nanjing

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

江苏省

市(区县):

南京市

Country:

China

Province:

Jiangsu

City:

单位(医院):

江苏省中西医结合医院

具体地址:

南京市红山路十字街100号

Institution
hospital:

Jiangsu Provincial Hospital on Traditional of Chinese and Western Medicine

Address:

100 Cross Street, Hongshan Road, Nanjing

经费或物资来源:

江苏省中医药管理局课题经费

Source(s) of funding:

Project Funds of Jiangsu Administration of Traditional Chinese Medicine

研究疾病:

脑梗死

研究疾病代码:

Target disease:

Cerebral infarction

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

I期临床试验

Phase I clinical trial

研究目的:

进一步优化汤针结合免疫调节康复方案(DAIRIES 方案),观察该方案对于改善脑梗死急性期火热证患者预后的疗效。

Objectives of Study:

To further optimize the combination of decoction and acupuncture with immune regulation and rehabilitation program (DAIRIES program), to observe the efficacy of this program in improving the prognosis of patients with acute cerebral infarction with heat syndrome.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

①符合《中国急性缺血性脑卒中诊治指南2014》脑梗死的诊断标准;②年龄18岁以上,90岁以下;③发病时间在72小时以内;④神经功能缺损NIHSS量表评分>4分;⑤同意参与本研究并签订知情同意书;⑤中医辨证属火热证证候。

Inclusion criteria

① In line with the diagnostic criteria of cerebral infarction in "China Guidelines for Diagnosis and Treatment of Acute Ischemic Stroke 2014"; ② Age above 18 years old and below 90 years old; ③ The onset time is within 72 hours; ④ Neurological deficit NIHSS score > 4 points; ⑤ Agree to participate in this research and sign the informed consent;⑥ TCM syndrome differentiation is heat syndrome.

排除标准:

①神经肌肉疾病;②全身性疾病或严重颅脑疾病导致意识、认知障碍(格拉斯哥昏迷评分(GCS)≤9分)短期内无恢复可能;③妊娠;④恶性肿瘤进展期;⑤放弃积极治疗的患者;⑥心肌梗塞急性期;⑦同时参加其他临床试验的患者;⑧研究人员认为其它原因不适合参与试验者。

Exclusion criteria:

① Neuromuscular disease; ② Consciousness and cognitive impairment caused by systemic disease or severe craniocerebral disease (Glasgow Coma Scale (GCS) ≤ 9 points), there is no possibility of recovery in the short term; ③ Pregnancy; ④ Progressive stage of malignant tumor; ⑤ Give up active treatment ⑥ The acute stage of myocardial infarction; ⑦ Patients who participated in other clinical trials at the same time; ⑧ Those who are considered unsuitable to participate in the trial for other reasons by the researchers.

研究实施时间:

Study execute time:

From 2022-01-01

To      2025-12-31

征募观察对象时间:

Recruiting time:

From 2022-05-01

To      2025-09-30

干预措施:

Interventions:

组别:

试验组(DAIRIES组)

样本量:

36

Group:

Experimental Group(DAIRIES Group)

Sample size:

干预措施:

在接受常规治疗同时进入DAIRIES方案(白虎汤化裁方辨证治疗联合超声指导下针灸穴位电刺激)进行康复治疗

干预措施代码:

Intervention:

On the basis of conventional treatment, entered DAIRIES program (Baihu Decoction combined with ultrasound-guided acupuncture and acupoint electrical stimulation) for rehabilitation treatment

Intervention code:

组别:

基础治疗组

样本量:

36

Group:

Basic treatment group

Sample size:

干预措施:

予常规治疗,并按临床惯例进行一般康复治疗

干预措施代码:

Intervention:

Basis of conventional treatment

Intervention code:

组别:

中药组

样本量:

36

Group:

Chinese medicine Group

Sample size:

干预措施:

常规治疗基础上予白虎汤化裁方治疗

干预措施代码:

Intervention:

On the basis of conventional treatment, Baihu Decoction was prescribed for treatment

Intervention code:

样本总量 Total sample size : 108

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

江苏省

市(区县):

南京市

Country:

China

Province:

Jiangsu

City:

Nanjing

单位(医院):

Jiangsu Province Academy of Traditional Chinese Medicine

单位级别:

三级甲等医院

Institution/hospital:

Jiangsu Provincial Hospital on Traditional of Chinese and Western Medicine

Level of the institution:

third-grade class-A hospital

测量指标:

Outcomes:

指标中文名:

院内感染发生率

指标类型:

次要指标

Outcome:

nosocomial infection rate

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肠壁增厚(BWT)

指标类型:

次要指标

Outcome:

Bowel wall thickening (BWT)

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

第7天NIHSS评分

指标类型:

次要指标

Outcome:

Day 7 NIHSS Score

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肠内营养达标时间

指标类型:

次要指标

Outcome:

Enteral nutrition compliance time

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

各项炎症指标

指标类型:

次要指标

Outcome:

inflammatory markers

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

90天时MRS评分

指标类型:

主要指标

Outcome:

MRS score at 90 days

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

胃动力及胃排空(GE)

指标类型:

次要指标

Outcome:

Gastric motility and gastric emptying (GE)

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肝肾功能

指标类型:

副作用指标

Outcome:

Liver and kidney function

Type:

Adverse events

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

第7天GCS评分

指标类型:

次要指标

Outcome:

Day 7 GCS Score

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

blood

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

征募研究对象情况:

尚未开始

Not yet recruiting

年龄范围:

最小 18
Min age years
最大 90
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

由课题组专人借助SAS(Ver10.0)统计分析系统产生108例受试者所接受处理(试验组、中药组、基础治疗组)的随机安排,即列出流水号为01~108所对应的治疗分配。

Randomization Procedure (please state who generates the random number sequence and by what method):

By using SAS (Ver10.0) statistical analysis system, specially-assigned persons in the research group generated the random arrangement of treatment (experimental group, Chinese medicine group, basic treatment group) for 108 subjects, that is, listed the treatment allocation corresponding to sequence numbers 01 ~ 108

盲法:

Blinding:

是否共享原始数据:

IPD sharing:

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

No sharing

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

No sharing

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

No sharing

数据管理委员会:

Data Managemen Committee:

Yes

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

国际传统医学临床试验注册平台 京ICP备07032215号-5 提示:推荐使用IE8.0以上版本 宽屏显示分辨率下使用系统